Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on April 1, 2020. The registrant is a Delaware corporation headquartered in San Diego, California, with common stock trading on the Nasdaq Capital Market under the symbol TROV.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance.
Material Changes
There are no material financial changes reported in this document. The primary event is the announcement that the Company's Phase 1b/2 clinical trial data for onvansertib will be presented at a major industry conference.
Outlook, Management Commentary, and Risks
- Clinical Trial Update: The Company announced that its Phase 1b/2 clinical trial of onvansertib in combination with standard-of-care FOLFIRI/Avastin (bevacizumab) for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC) will be featured at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
- Event Details: The ASCO Annual Meeting is scheduled to be held from May 29 to June 2, 2020.
- Exhibit: A copy of the press release regarding this presentation is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the exact date and session of the presentation at the 2020 ASCO Annual Meeting.
- Review the full text of the press release (Exhibit 99.1) for specific clinical data points or preliminary results.
- Confirm the current status of the onvansertib development program and any subsequent regulatory filings.
- Check for any updates regarding the Company's cash position and runway, as this filing does not contain financial data.